Merck & Co. (MRK) : James Investment Research Inc scooped up 62,435 additional shares in Merck & Co. during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 15, 2016. The investment management firm now holds a total of 747,627 shares of Merck & Co. which is valued at $44,124,946.Merck & Co. makes up approximately 1.09% of James Investment Research Inc’s portfolio.
Other Hedge Funds, Including , Crestpoint Capital Management reduced its stake in MRK by selling 500 shares or 1.69% in the most recent quarter. The Hedge Fund company now holds 29,000 shares of MRK which is valued at $1,711,580. Merck & Co. makes up approx 0.88% of Crestpoint Capital Management’s portfolio.Eqis Capital Management reduced its stake in MRK by selling 113 shares or 0.73% in the most recent quarter. The Hedge Fund company now holds 15,441 shares of MRK which is valued at $911,328. Merck & Co. makes up approx 0.06% of Eqis Capital Management’s portfolio. Maple Securities Usa Inc sold out all of its stake in MRK during the most recent quarter. The investment firm sold 37,105 shares of MRK which is valued $2,209,603.Hollencrest Securities boosted its stake in MRK in the latest quarter, The investment management firm added 14,097 additional shares and now holds a total of 93,597 shares of Merck & Co. which is valued at $5,554,982. Merck & Co. makes up approx 0.86% of Hollencrest Securities’s portfolio.
Merck & Co. closed down -0.61 points or -1.02% at $59.02 with 87,69,171 shares getting traded on Monday. Post opening the session at $59, the shares hit an intraday low of $58.715 and an intraday high of $59.49 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Merck & Co. reported $0.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 5, 2016. Analyst had a consensus of $0.85. The company had revenue of $9312.00 million for the quarter, compared to analysts expectations of $9445.10 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.85 EPS.
Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Companys animal health products are sold to veterinarians distributors and animal producers.